Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Resubmits Gimoti™ New Drug Application to FDA
SOLANA BEACH, Calif. , Dec. 20, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S.
View HTML
Toggle Summary Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
SOLANA BEACH, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has successfully completed patient enrollment in its pivotal Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms
View HTML
Toggle Summary Evoke to Participate in the Brean Capital 2015 Life Sciences Summit
SOLANA BEACH, Calif. , Nov. 10, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer , R.Ph., President and CEO will be participating in the Brean Capital 2015 Life
View HTML
Toggle Summary FDA Accepts Evoke Pharma’s NDA Resubmission for Gimoti™
PDUFA Target Goal Date is June 19, 2020 SOLANA BEACH, Calif. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the U.S.
View HTML
Toggle Summary FDA Approves Evoke’s GIMOTI™
Commercial Partner EVERSANA Prepares for GIMOTI Launch Evoke Extends Cash Runway into 2021 SOLANA BEACH, Calif. , June 19, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that
View HTML
Toggle Summary FDA Approves PDUFA Fee Waiver for Gimoti™ New Drug Application
Cash runway updated into October 2018 SOLANA BEACH, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that the U.S.
View HTML
Toggle Summary FDA Exempts Evoke from Requirement for Human Factor Validation Study
Company reaffirms NDA submission by year end 2017
View HTML
Toggle Summary GIMOTI® Commercialization Update
New Research Study Demonstrates Increased Acceptance Among Healthcare Providers Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com   Expanded Coverage with recent New York Medicaid Approval SOLANA BEACH, Calif. , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma ,
View HTML
Toggle Summary Patient Experience Survey Reported Positive Findings for GIMOTI®
Research Study Among Patients Demonstrated Favorable Acceptance and Utilization of GIMOTI SOLANA BEACH, Calif. and CHICAGO , May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and
View HTML
Toggle Summary Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma's Proposed Comparative Exposure PK Trial for Gimoti NDA
SOLANA BEACH, Calif., April 04, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company recently completed a positive Type A meeting with the U.S.
View HTML